Edoxaban
Edoxaban is a direct oral anticoagulant (DOAC) that works by selectively blocking Factor Xa, a key enzyme in the blood clotting process. It is prescribed to reduce the risk of stroke and blood clots in patients with non-valvular atrial fibrillation, and to treat and prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE).
Edoxaban is an anticoagulant medication that prevents blood clots by inhibiting Factor Xa, used for stroke prevention in atrial fibrillation and treatment of DVT/PE.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- B01AF03
- RxNorm
- 1599538
- Generic
- Edoxaban
- Class
- atc-b01
- Brands
- Savaysa
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE.
Edoxaban is a direct, selective inhibitor of Factor Xa (FXa). It does not require antithrombin III for its anticoagulant activity. By inhibiting free FXa and prothrombinase activity, it reduces thrombin generation and subsequently inhibits thrombin-induced platelet aggregation, preventing clot formation.
Like all anticoagulants, edoxaban carries a significant risk of bleeding and should not be used in patients with active pathological bleeding. It is not recommended for patients with mechanical heart valves or moderate-to-severe mitral stenosis. Dosage may require adjustment based on renal function, body weight, and concomitant medications. Patients should not discontinue edoxaban abruptly without medical consultation as this can increase the risk of thrombotic events.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy